Floatz logo

TRASTUZUMAB

Chemotherapeutic Agent Toxicity

Daping Hospital and the Research Institute of Surgery of the Third Military Medical Universitymonoclonal_antibodyPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

65 Active assets in the Chemotherapeutic Agent Toxicity cohort.

View all 50

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →